Research ArticleTheranostics
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang, Shaobo Yao, Chunmei Bai, Hong Zhao, Ru Jia, Jianming Xu and Li Huo
Journal of Nuclear Medicine June 2020, 61 (6) 897-903; DOI: https://doi.org/10.2967/jnumed.119.235093
Wenjia Zhu
1Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yuejuan Cheng
2Department of Oncology, Peking Union Medical College Hospital, Beijing, China
Xuezhu Wang
1Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Shaobo Yao
3Department of PET/CT Diagnostics, General Hospital, Tianjin Medical University Tianjin, China
Chunmei Bai
2Department of Oncology, Peking Union Medical College Hospital, Beijing, China
Hong Zhao
4Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and
Ru Jia
5Department of Gastrointestinal Oncology, Fifth Medical Center, General Hospital of PLA, Beijing, China
Jianming Xu
5Department of Gastrointestinal Oncology, Fifth Medical Center, General Hospital of PLA, Beijing, China
Li Huo
1Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 6
June 1, 2020
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang, Shaobo Yao, Chunmei Bai, Hong Zhao, Ru Jia, Jianming Xu, Li Huo
Journal of Nuclear Medicine Jun 2020, 61 (6) 897-903; DOI: 10.2967/jnumed.119.235093
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang, Shaobo Yao, Chunmei Bai, Hong Zhao, Ru Jia, Jianming Xu, Li Huo
Journal of Nuclear Medicine Jun 2020, 61 (6) 897-903; DOI: 10.2967/jnumed.119.235093
Jump to section
Related Articles
Cited By...
- SSTR Antagonists as Theranostic Option in Merkel Cell Carcinoma
- 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
- Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
- The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?
- 18F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors